中国组织工程研究

中国组织工程研究 ›› 2012, Vol. 16 ›› Issue (36): 6748-6752.doi: 10.3969/j.issn.2095-4344.2012.36.017

• 干细胞因子及调控因子 stem cell factors and regulatory factors • 上一篇    下一篇

急性髓系白血病细胞血管细胞黏附分子1、CD34和CD117的表达

庞文正，滕淑萍，侯丽君   

  1. 中山大学附属第五医院血液风湿科，广东省珠海市 519000
  • 收稿日期:2011-10-09 修回日期:2011-11-22 出版日期:2012-09-02 发布日期:2012-09-02
  • 通讯作者: 侯丽君，主任医师，中山大学附属第五医院血液风湿科，广东省珠海市519000 zhcz_001@sina.com lijun_hou@163.com
  • 作者简介:庞文正★，男，1981年生，河北省沧州市人，汉族， 2009年中山大学毕业，硕士，医师，主要从事白血病基质细胞研究。 pangwenzheng521@163.com

Expression of vascular cell adhesion molecule 1, CD34 and CD117 on acute myeloblastic leukemia cells

Pang Wen-zheng, Teng Shu-ping, Hou Li-jun   

  1. Department of Hematology and Rheumatology, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, Guangdong Province, China
  • Received:2011-10-09 Revised:2011-11-22 Online:2012-09-02 Published:2012-09-02
  • Contact: Hou Li-jun, Chief physician, Department of Hematology and Rheumatology, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, Guangdong Province, China zhcz_001@sina.com lijun_hou@163.com
  • About author:Pang Wen-zheng★, Master, Physician, Department of Hematology and Rheumatology, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, Guangdong Province, China pangwenzheng521@163.com

PDF

452

被引次数

2

摘要：

背景：血管细胞黏附分子1与白血病浸润密切相关，白血病细胞本身是否表达血管细胞黏附分子1，以及与疾病难治是否相关尚无定论。
目的：分析血管细胞黏附分子1、CD34、CD117在急性髓系白血病细胞表面的表达，3者之间的相互关系及与难治性急性髓系白血病的相关性。
方法：采用流式细胞技术检测16例急性髓系白血病细胞中血管细胞黏附分子1、CD34、CD117的表达，其中难治组6例，非难治组10例；同时以正常骨髓单个核细胞标本作对照。
结果与结论：急性髓系白血病细胞CD34、CD117表达高于对照组(P < 0.05)。难治组急性髓系白血病细胞CD34表达明显高于非难治组(P < 0.05)。难治组与非难治组CD117表达差异无显著性意义(P > 0.05)。急性髓系白血病细胞血管细胞黏附分子1表达与对照组比较差异无显著性意义(P > 0.05)。难治组与非难治组血管细胞黏附分子1表达差异无显著性意义(P > 0.05)。表明急性髓系白血病细胞伴CD34表达，为不良预后指标之一，CD117、血管细胞黏附分子1表达与其是否难治无明显相关性。

关键词: 急性髓系白血病, 血管细胞黏附分子1, CD34, CD117, 骨髓单个核细胞, 干细胞

Abstract:

BACKGROUND: Vascular cell adhesion molecule 1 (VCAM-1) is closely related to the infiltration of leukemia. The reports on whether leukemia cells can express VCAM-1 or not, and whether there is a relationship between refractory leukemia and VCAM-1 are inconclusive.
OBJECTIVE: To study the expression of VCAM-1, CD34, CD117 on acute myeloid leukemia cells surface, investigate the relationship between them and the treatment effect of them on refractory acute myeloid leukemia.
METHODS: The expression of VCAM-1, CD34, CD117 in acute myeloid leukemia cells from 16 patients were detected by flow cytometry. There were six patients in the refractory group and 10 patients in non-refractory group. Normal bone marrow mononuclear cells were regarded as control group.
RESULTS AND CONCLUSION: The expressions of CD34 and CD117 on acute myeloid leukemia cells were higher than those in the control group (P < 0.05). The expression of acute myeloid leukemia cells CD34 in the refractory group was significantly higher than that in the non-refractory group (P < 0.05). There was no significant difference in CD117 expression on acute myeloid leukemia between refractory group and non-refractory group (P > 0.05). The expression of VCAM-1 on acute myeloid leukemia cells was not significantly different compared with the control group
(P > 0.05). There was no significant difference in expression of VCAM-1 on acute myeloid leukemia between refractory group and non-refractory group (P > 0.05). Acute myeloid leukemia cells with CD34 expression is one of indices for
poor prognosis and the expression of CD117 and VCAM-1 has no significant correlation with treatment of refractory acute myeloid leukemia.

中图分类号: